EUVIMEDEUVIMED entdecken
Crossref

Ethnopharmacology in Combating Emerging Diseases: Lessons from COVID-19 in Nigeria

Emmanuel Agbamu, Triumph Balogun, Promise Kamsiyochukwu Okoro, Kabeerat Arike Balogun, Justinah Ekpoboredefe, Nduka Godsgift Iteh, Christabel Ebulu

Journal of Exploratory Research in Pharmacology · 30.09.2026 · 11 (3)

DOI: 10.14218/jerp.2026.00004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Exploratory Research in Pharmacology, online erschienen am 30.07.2026. Verfasst von Emmanuel Agbamu und 6 weiteren Autor:innen. Die Arbeit nennt 77 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emerging diseases are those that appear in a population for the first time or previously existed, but rapidly increase in incidence or geographic range. During the coronavirus disease 2019 (COVID-19) pandemic, ethnopharmacological practices became prominent in Nigeria because herbal remedies were affordable, locally accessible, and supported by longstanding cultural trust. However, despite broad public use and some regulatory progress, evidence for the safety, efficacy, standardization, and clinical application of these remedies remains limited. This narrative review examines the integration of ethnopharmacology into Nigeria’s COVID-19 response, evaluates its strengths, constraints, and lessons, and considers future pathways for incorporating ethnopharmacological practices into epidemic preparedness and response strategies. It reviews literature and regulatory information published from 2015 to 2025, focusing on herbal remedies used during the pandemic, regulatory listing processes, and key research gaps. Common remedies were derived from Zingiber officinale, Allium sativum, Citrus limon, Curcuma longa, and Garcinia kola. The National Agency for Food and Drug Administration and Control in Nigeria accelerated toxicological testing and listed 14 local herbal medicines, including Pax Herbal Cugzin, Niprimune, and IHP Detox Tea. This established a baseline safety for human consumption but did not validate therapeutic efficacy against severe acute respiratory syndrome coronavirus 2, which requires rigorous clinical trials. Although some formulations showed promising findings in preliminary clinical, in silico, and in vitro studies, the evidence was constrained by small pilot samples, absence of multiphase randomized controlled trials, insufficient in vivo pharmacokinetic data, and difficulties in isolating active compounds necessary for batch-to-batch consistency. Strengthening Nigeria’s resilience to future epidemics will require sustained investment in scientific research infrastructure, toxicogenomic and metabolomic studies, robust intellectual property frameworks for indigenous knowledge, and transparent public communication to reduce misinformation and product misuse.

Zitieren

APA

Agbamu, E., Balogun, T., Okoro, P. K., Balogun, K. A., Ekpoboredefe, J., Iteh, N. G., & Ebulu, C. (2026). Ethnopharmacology in Combating Emerging Diseases: Lessons from COVID-19 in Nigeria. Journal of Exploratory Research in Pharmacology, 11(3). https://doi.org/10.14218/jerp.2026.00004

Vancouver

Agbamu E, Balogun T, Okoro PK, Balogun KA, Ekpoboredefe J, Iteh NG, et al. Ethnopharmacology in Combating Emerging Diseases: Lessons from COVID-19 in Nigeria. Journal of Exploratory Research in Pharmacology. 2026;11(3). doi:10.14218/jerp.2026.00004

BibTeX
@article{Agbamu2026,
  author = {Agbamu, Emmanuel and Balogun, Triumph and Okoro, Promise Kamsiyochukwu and Balogun, Kabeerat Arike and Ekpoboredefe, Justinah and Iteh, Nduka Godsgift and Ebulu, Christabel},
  title = {Ethnopharmacology in Combating Emerging Diseases: Lessons from COVID-19 in Nigeria},
  journal = {Journal of Exploratory Research in Pharmacology},
  year = {2026},
  volume = {11},
  number = {3},
  doi = {10.14218/jerp.2026.00004}
}
Kostenlos starten →